Brainstorm Cell Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Brainstorm Cell Therapeutics

10/05/2024 16:56

* Brainstorm Cell Therapeutics Inc  BCLI.OQ   BCLI.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 13 (estimated) for the period ending January
1 0001
    * 
    * ​LSEG's mean analyst estimate for Brainstorm Cell
Therapeutics
Inc is for a loss of 7 cents per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Hold".​
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $2.50​, above​ its last closing price
of $0.47. ​​​

This summary was machine generated May 10 at 15:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)